8-KLeadership ChangesExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Apr 26, 2023)

Filed April 26, 2023For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb Company (BMY) announced a significant leadership transition, with current Chairman and CEO Giovanni Caforio, M.D., set to retire as CEO on November 1, 2023. Dr. Caforio will remain Chairman until his CEO retirement and then transition to Executive Chairman for a period to be determined. This marks the end of an era for a key figure in the company's recent history. Following this announcement, the Board of Directors appointed Christopher Boerner, Ph.D., as the new Chief Executive Officer, effective November 1, 2023. Dr. Boerner, currently serving as Chief Operating Officer, has been with BMY since 2015 and has held various senior leadership roles, including Executive Vice President and Chief Commercialization Officer. His appointment signals a move towards internal succession for the top leadership role.

Key Highlights

  • 1CEO Giovanni Caforio, M.D., will retire on November 1, 2023, after leading the company as CEO.
  • 2Dr. Caforio will transition to Executive Chairman for a defined period following his CEO retirement.
  • 3Christopher Boerner, Ph.D., has been appointed as the new CEO, effective November 1, 2023.
  • 4Dr. Boerner, currently COO, has been with Bristol Myers Squibb since 2015 and has a strong commercial background.
  • 5Dr. Boerner's base salary will increase to $1,300,000 and his target cash incentive opportunity will increase to $1,560,000 in his new COO role.
  • 6Further compensation details for Dr. Boerner's CEO role and Dr. Caforio's Executive Chairman role will be disclosed later.

Frequently Asked Questions

Dr. Giovanni Caforio, M.D., will retire as Chief Executive Officer on November 1, 2023. Christopher Boerner, Ph.D., will assume the CEO role on the same date.

Dr. Caforio will continue as Chairman of the Board until November 1, 2023, and then transition to serve as Executive Chairman of the Board for a transition period to be determined by the Board.

Dr. Boerner has been with Bristol Myers Squibb since 2015 and has held several senior positions, including Executive Vice President and Chief Commercialization Officer, and most recently, Chief Operating Officer. He has a strong track record within the company.

Effective April 26, 2023, in his role as Chief Operating Officer, his annual base salary increased from $1,115,000 to $1,300,000, and his annual target cash incentive opportunity increased from $1,115,000 to $1,560,000. Specific compensation details for his CEO role will be disclosed later.